

Masaru Enomoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4324494/publications.pdf>

Version: 2024-02-01

170
papers

3,385
citations

147566

31
h-index

197535

49
g-index

174
all docs

174
docs citations

174
times ranked

4449
citing authors

#	ARTICLE	IF	CITATIONS
1	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 874-885.e4.	2.4	4
2	On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. <i>Liver International</i> , 2022, 42, 59-68.	1.9	10
3	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2022, 16, 48-58.	1.9	7
4	Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment. <i>Scientific Reports</i> , 2022, 12, 105.	1.6	3
5	Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0263844.	1.1	5
6	Hepatocellular Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?. <i>Hepatology Communications</i> , 2022, 6, 445-447.	2.0	0
7	Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas. <i>Oncology</i> , 2021, 99, 186-191.	0.9	13
8	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 46-60.e8.	2.4	27
9	Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 217-224.	1.4	5
10	Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein. <i>Gut</i> , 2021, 70, 1199-1201.	6.1	7
11	Outcome of nucleos(t)ide analog intervention in patients with preventive or on-demand therapy for hepatitis B virus reactivation. <i>Journal of Medical Virology</i> , 2021, 93, 3679-3687.	2.5	5
12	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 71-81.	1.9	14
13	Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed. <i>Internal Medicine</i> , 2021, 60, 3441-3445.	0.3	2
14	Establishing Efficient Systems through Electronic Medical Records to Promote Intra-hospital Referrals of Hepatitis Virus Carriers to Hepatology Specialists: A Multicenter Questionnaire-based Survey of 1,281 Healthcare Professionals. <i>Internal Medicine</i> , 2021, 60, 337-343.	0.3	10
15	Combination of Entecavir or Tenofovir with Pegylated Interferon- α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1456.	1.8	6
16	Present status of hepatitis medical care coordinators in regional core centers in Japan. <i>Acta Hepatologica Japonica</i> , 2021, 62, 96-98.	0.0	3
17	Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2021, 60, 545-552.	0.3	2
18	Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. <i>American Journal of Gastroenterology</i> , 2021, 116, 1264-1273.	0.2	12

#	ARTICLE	IF	CITATIONS
19	Perâ€rectal portal scintigraphy as an alternative measure of hepatic venous pressure gradient in chronic liver disease: A preliminary report. <i>Clinical Physiology and Functional Imaging</i> , 2021, 41, 334-341.	0.5	1
20	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1890-1899.	1.9	40
21	Validation of a twoâ€step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis. <i>JGH Open</i> , 2021, 5, 801-808.	0.7	2
22	Anti-fibrotic treatments for chronic liver diseases: The present and the future. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 413-424.	4.5	23
23	I shall be released (from infinite HBV nucleos(t)ide analog therapy): Japanese experience. <i>Journal of Hepatology</i> , 2021, 75, 1496-1497.	1.8	1
24	Successful Transcatheter Arterial Embolization for Hemothorax from a Spontaneous Rupture of Hepatocellular Carcinoma Metastasis to the Chest Wall in an Elderly Patient. <i>Internal Medicine</i> , 2021, 60, 2223-2228.	0.3	3
25	The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. <i>Scientific Reports</i> , 2021, 11, 13844.	1.6	14
26	A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. <i>PLoS ONE</i> , 2021, 16, e0257166.	1.1	5
27	Lenvatinib-Induced Tumor-Related Hemorrhage in Patients With Unresectable Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2021, 116, 631-631.	0.2	5
28	Directâ€Acting Antivirals Reduce the Risk of Tumor Progression of Hepatocellular Carcinoma after Curative Treatment. <i>Journal of Viral Hepatitis</i> , 2021, , .	1.0	2
29	Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study. <i>BMC Gastroenterology</i> , 2021, 21, 489.	0.8	0
30	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 389-399.	1.9	58
31	Cure With Interferonâ€Free Directâ€Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virusâ€Related Hepatocellular Carcinoma From Both East and West. <i>Hepatology</i> , 2020, 71, 1910-1922.	3.6	70
32	The Moral of Hepatic Fibrosis: Donâ€™t Always Believe Noninvasive Fibrosis Measurements. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1293-1295.	1.1	4
33	Development of a novel anti-hepatitis B virus agent via Sp1. <i>Scientific Reports</i> , 2020, 10, 47.	1.6	8
34	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 271-280.	0.2	72
35	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. <i>Clinical Infectious Diseases</i> , 2020, 71, 2840-2848.	2.9	30
36	Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2020, 55, 977-989.	2.3	8

#	ARTICLE	IF	CITATIONS
37	Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. <i>Cancers</i> , 2020, 12, 2045.	1.7	12
38	High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use. <i>JGH Open</i> , 2020, 4, 964-969.	0.7	3
39	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020, 14, 1023-1033.	1.9	38
40	Risk factors for hepatocellular carcinoma in treated chronic hepatitis C patients—Relationship to smoking and alcohol. <i>JGH Open</i> , 2020, 4, 867-875.	0.7	3
41	Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients. <i>Annals of Hepatology</i> , 2020, 19, 367-372.	0.6	5
42	Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 860-866.	0.4	2
43	Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4517.	1.8	3
44	Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 3392.	1.6	46
45	The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B. <i>Internal Medicine</i> , 2020, 59, 205-210.	0.3	2
46	Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease. <i>Hepatology Communications</i> , 2020, 4, 284-297.	2.0	53
47	TGF- β 1-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2020, 73, 882-895.	1.8	24
48	Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1039-1052.	3.7	70
49	A case of ectopic hepatocellular carcinoma originating from the retroperitoneum. <i>Acta Hepatologica Japonica</i> , 2020, 61, 597-606.	0.0	0
50	Last crusade against HCV: Direct-acting antiviral treatment for marginalized populations. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1501-1501.	1.0	0
51	Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world. <i>Hepatology Research</i> , 2019, 49, 1365-1373.	1.8	20
52	Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response. <i>Biomedicines</i> , 2019, 7, 87.	1.4	20
53	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019, 13, 587-598.	1.9	27
54	Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse?. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 598-602.	0.4	3

#	ARTICLE	IF	CITATIONS
55	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 473-485.	1.8	62
56	Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 355-360.	0.4	7
57	Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial. <i>Journal of Medical Virology</i> , 2019, 91, 1295-1300.	2.5	10
58	A case series of five patients with hepatic sarcoidosis diagnosed by liver biopsy. <i>Acta Hepatologica Japonica</i> , 2019, 60, 405-413.	0.0	1
59	Association between HLA-DQA1/DRB1 polymorphism and development of hepatocellular carcinoma during entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 937-946.	1.4	9
60	Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 213-217.	0.4	0
61	The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort. <i>Journal of Viral Hepatitis</i> , 2018, 25, 535-542.	1.0	11
62	Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B. <i>Hepatology Research</i> , 2018, 48, 459-468.	1.8	4
63	A Clinical Quantitative Evaluation of Hepatobiliary Transport of [¹¹ C]Dehydropravastatin in Humans Using Positron Emission Tomography. <i>Drug Metabolism and Disposition</i> , 2018, 46, 719-728.	1.7	49
64	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. <i>Journal of Gastroenterology</i> , 2018, 53, 247-257.	2.3	15
65	Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2018, 25, 608-611.	1.0	30
66	Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. <i>United European Gastroenterology Journal</i> , 2018, 6, 1391-1400.	1.6	22
67	Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 857-864.	1.1	6
68	Remission of Psoriasis After Treatment of Chronic Hepatitis C Virus Infection With Direct-Acting Antivirals. <i>Annals of Internal Medicine</i> , 2018, 168, 678-680.	2.0	7
69	Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication. <i>PLoS ONE</i> , 2018, 13, e0194163.	1.1	11
70	Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1495-1502.	1.4	10
71	Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?. <i>Gastroenterology</i> , 2017, 153, 327-328.	0.6	1
72	Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 11912.	1.6	28

#	ARTICLE	IF	CITATIONS
73	Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1095-1104.	1.4	21
74	Infection route of hepatitis C patients treated with direct-acting antivirals -To evaluate the risk of reinfection-. <i>Acta Hepatologica Japonica</i> , 2017, 58, 435-440.	0.0	0
75	Hepatitis B virus infection and alcohol consumption. <i>World Journal of Gastroenterology</i> , 2017, 23, 2651.	1.4	49
76	Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed. <i>International Journal of Molecular Sciences</i> , 2017, 18, 962.	1.8	5
77	Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination. <i>Annals of Hepatology</i> , 2017, 16, 734-741.	0.6	9
78	Recent Advances in Antiviral Therapy for Chronic Hepatitis C. <i>Mediators of Inflammation</i> , 2016, 2016, 1-11.	1.4	49
79	Putting "sticky notes" on the electronic medical record to promote intra-hospital referral of hepatitis B and C virus-positive patients to hepatology specialists: an exploratory study. <i>BMC Infectious Diseases</i> , 2016, 16, 410.	1.3	18
80	A case of hepatitis C virus-associated mixed cryoglobulinemic vasculitis treated with daclatasvir and asunaprevir. <i>Acta Hepatologica Japonica</i> , 2016, 57, 328-333.	0.0	1
81	Promotion of intra-hospital referral of hepatitis B and C virus carriers to hepatology specialists by electronic medical record-based alert system: a case study at a university hospital. <i>Acta Hepatologica Japonica</i> , 2016, 57, 7-16.	0.0	9
82	Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with hepatitis C virus genotype 1b. <i>Hepatology Research</i> , 2016, 46, 1311-1320.	1.8	8
83	MicroRNA expression in hepatocellular carcinoma after the eradication of chronic hepatitis virus C infection using interferon therapy. <i>Hepatology Research</i> , 2016, 46, E26-35.	1.8	15
84	Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy. <i>Annals of Hepatology</i> , 2015, 14, 28-35.	0.6	4
85	Development of novel hepatitis B virus capsid inhibitor using in silico screening. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 1165-1175.	1.0	10
86	Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon- β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 613-620.	0.5	5
87	Discovering novel direct acting antiviral agents for HBV using in silico screening. <i>Biochemical and Biophysical Research Communications</i> , 2015, 456, 20-28.	1.0	10
88	Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1715-1721.	1.4	23
89	Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver. <i>Laboratory Investigation</i> , 2014, 94, 192-207.	1.7	48
90	Adjuvant epoetin- α with peginterferon- α and ribavirin in Japanese ribavirin-intolerant relapsed patients with chronic hepatitis C genotype 2. <i>Hepatology Research</i> , 2014, 44, E290-6.	1.8	1

#	ARTICLE	IF	CITATIONS
91	Positioning of ¹⁸ F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1722-1727.	1.4	14
92	Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated interferon and ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 201-207.	1.4	13
93	Interferon- α 2 for treatment of chronic hepatitis C infection in the era of direct-acting antiviral agents. <i>Hepatology Research</i> , 2014, 44, 371-376.	1.8	3
94	Comparison of Hepatocellular Carcinoma miRNA Expression Profiling as Evaluated by Next Generation Sequencing and Microarray. <i>PLoS ONE</i> , 2014, 9, e106314.	1.1	74
95	Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2014, 20, 12031.	1.4	21
96	Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. <i>Journal of Gastroenterology</i> , 2013, 48, 999-1005.	2.3	19
97	Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for "middle"? <i>Journal of Gastroenterology</i> , 2013, 48, 555-556.	2.3	1
98	Entecavir and interferon- α 2 sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2013, 48, 397-404.	2.3	20
99	A pregnant woman with acute hepatitis B in whom vertical transmission was prevented by tenofovir disoproxil fumarate. <i>Clinical Journal of Gastroenterology</i> , 2013, 6, 173-176.	0.4	2
100	Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. <i>Hepatology Research</i> , 2013, 43, 1264-1275.	1.8	91
101	Combination therapy of natural human interferon- β and ribavirin for chronic hepatitis C patients with injection drug use. <i>Hepatology Research</i> , 2013, 43, 1013-1019.	1.8	3
102	A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2013, 52, 1589-1592.	0.3	12
103	Effect of Caffeine-Containing Beverage Consumption on Serum Alanine Aminotransferase Levels in Patients with Chronic Hepatitis C Virus Infection: A Hospital-Based Cohort Study. <i>PLoS ONE</i> , 2013, 8, e83382.	1.1	6
104	Real-time PCR assays for hepatitis C virus RNA (genotype 1) is useful for evaluating virological response to the treatment with peginterferon-alpha2b and ribavirin. <i>Osaka City Medical Journal</i> , 2013, 59, 79-89.	0.4	0
105	Anti-hepatitis B virus therapy: To stop, or not to stop: Has the question been solved?. <i>Hepatology Research</i> , 2012, 42, 946-947.	1.8	1
106	MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. <i>Gut</i> , 2012, 61, 1600-1609.	6.1	212
107	Induction of microRNA-214-5p in human and rodent liver fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, 12.	3.4	73
108	Effect of Mosapride Citrate on Gastric Emptying in Interferon-Induced Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1510-1516.	1.1	23

#	ARTICLE	IF	CITATIONS
109	Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. <i>Hepatology Research</i> , 2012, 42, 549-557.	1.8	10
110	Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon- α and ribavirin therapy, and efficacy of retreatment. <i>Hepatology Research</i> , 2012, 42, 1157-1167.	1.8	13
111	Nutritional status in relation to lifestyle in patients with compensated viral cirrhosis. <i>World Journal of Gastroenterology</i> , 2012, 18, 5759.	1.4	32
112	Benefits of artificially induced pleural effusion and/or ascites for percutaneous radiofrequency ablation of hepatocellular carcinoma located on the liver surface and in the hepatic dome. <i>Hepato-Gastroenterology</i> , 2012, 59, 546-50.	0.5	8
113	High prevalence of hepatitis C virus infection in Airin district, Osaka, Japan: A hospital-based study of 1162 patients. <i>Hepatology Research</i> , 2011, 41, 731-737.	1.8	3
114	Close correlation of liver stiffness with collagen deposition and presence of myofibroblasts in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2011, 41, 897-903.	1.8	16
115	Favorable factors for retreatment with pegylated interferon λ 2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus. <i>Hepatology Research</i> , 2011, 41, 1169-1177.	1.8	4
116	Real-time tissue elastography as a tool for the noninvasive assessment of liver stiffness in patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2011, 46, 350-358.	2.3	83
117	Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. <i>Journal of Gastroenterology</i> , 2011, 46, 556-564.	2.3	135
118	Could Trastuzumab Suppress Hepatitis C Virus in a Patient With Chronic Hepatitis and Breast Cancer?. <i>American Journal of Gastroenterology</i> , 2011, 106, 1865-1866.	0.2	2
119	Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. <i>Journal of Viral Hepatitis</i> , 2010, 17, 123-129.	1.0	48
120	Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. <i>Hepatology Research</i> , 2010, 40, 853-861.	1.8	51
121	Sildenafil-Induced Severe Cholestatic Hepatotoxicity. <i>American Journal of Gastroenterology</i> , 2009, 104, 254-255.	0.2	9
122	Applicability of BARD score to Japanese patients with NAFLD. <i>Gut</i> , 2009, 58, 1566-1567.	6.1	37
123	Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. <i>Journal of Medical Virology</i> , 2009, 81, 1009-1014.	2.5	31
124	A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: Validation using prognostic markers for pre-liver transplant status. <i>Liver Transplantation</i> , 2009, 15, 790-797.	1.3	50
125	Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , 2009, 44, 608-614.	2.3	38
126	Two cases of hepatocellular adenomatosis treated with transcatheter arterial embolization. <i>Hepatology International</i> , 2009, 3, 416-420.	1.9	18

#	ARTICLE	IF	CITATIONS
127	Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection. <i>Liver International</i> , 2009, 29, 126-132.	1.9	19
128	Emerging Antiviral Drugs for Hepatitis C Virus. <i>Reviews on Recent Clinical Trials</i> , 2009, 4, 179-184.	0.4	8
129	A case of primary small cell carcinoma of the liver that was treated with chemotherapy. <i>Hepatology International</i> , 2008, 2, 500-4.	1.9	12
130	Platelet-associated IgG for the diagnosis of immune thrombocytopaenic purpura during peginterferon α 2a and ribavirin treatment for chronic hepatitis C. <i>Liver International</i> , 2008, 28, 1314-1315.	1.9	3
131	Optimal duration of additional therapy after biochemical and virological responses to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomized trial. <i>Hepatology Research</i> , 2008, 38, 954-959.	1.8	7
132	Entecavir to Treat Hepatitis B-associated Cryoglobulinemic Vasculitis. <i>Annals of Internal Medicine</i> , 2008, 149, 912.	2.0	29
133	Lamivudine and IFN- α 2a Sequential Therapy in HBe Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 201-208.	0.5	8
134	Laparoscopic observation of 2 cases of nodular regenerative hyperplasia of the liver. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 171-173.	0.5	1
135	Expression of Connective Tissue Growth Factor in the Human Liver with Idiopathic Portal Hypertension. <i>Molecular Medicine</i> , 2007, 13, 240-245.	1.9	29
136	Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: Analyses of the polymerase gene and full-length sequences. <i>Journal of Medical Virology</i> , 2007, 79, 1664-1670.	2.5	22
137	Plummer-Vinson syndrome successfully treated by endoscopic dilatation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 2348-2351.	1.4	13
138	Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. <i>Liver International</i> , 2007, 27, 95-100.	1.9	12
139	Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. <i>Liver International</i> , 2007, 27, 186-191.	1.9	78
140	A case of sclerosing cholangitis with autoimmune pancreatitis evaluated by FDG-PET. <i>Annals of Nuclear Medicine</i> , 2007, 21, 223-228.	1.2	16
141	Interferon- α plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial. <i>Gut</i> , 2006, 55, 139-140.	6.1	14
142	Hepatitis B virus genotypes and response to antiviral therapy. <i>Clinical Laboratory</i> , 2006, 52, 43-7.	0.2	37
143	Alcohol abuse as an etiologic factor for hepatocellular carcinoma in Japan. <i>Hepatology Research</i> , 2005, 31, 73-78.	1.8	4
144	Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. <i>Journal of Medical Virology</i> , 2005, 75, 235-239.	2.5	63

#	ARTICLE	IF	CITATIONS
145	Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon- α 2b and ribavirin therapy in patients with genotype 1 and high viral loads. <i>Journal of Medical Virology</i> , 2005, 77, 77-82.	2.5	13
146	Alteration of Gene Expression in Human Hepatocellular Carcinoma with Integrated Hepatitis B Virus DNA. <i>Clinical Cancer Research</i> , 2005, 11, 5821-5826.	3.2	72
147	Adefovir Dipivoxil to Prevent Exacerbation of Lamivudine-resistant Hepatitis B Infection during Chemotherapy for Non-Hodgkin's Lymphoma. <i>American Journal of Gastroenterology</i> , 2004, 99, 1619-1620.	0.2	13
148	Effects of ribavirin combined with interferon-alpha2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. <i>Journal of Viral Hepatitis</i> , 2004, 11, 448-454.	1.0	12
149	Codeine Phosphate-Induced Hypersensitivity Syndrome. <i>Annals of Pharmacotherapy</i> , 2004, 38, 799-802.	0.9	11
150	Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. <i>Journal of Medical Virology</i> , 2003, 69, 475-481.	2.5	27
151	Meshwork pattern is an important risk factor for development of hepatocellular carcinoma in patients with HBV-related chronic hepatitis and cirrhosis. <i>Hepatology Research</i> , 2003, 25, 166-173.	1.8	2
152	Effect of oral supplementation with branched-chain amino acid granules on serum albumin level in the early stage of cirrhosis: a randomized pilot trial. <i>Hepatology Research</i> , 2003, 25, 312-318.	1.8	39
153	Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan) <i>Tj ETQq1 1 0.784314 rgBT /O</i> 125-133.	1.8	20
154	Association of HLA Alleles with Response (Especially Biochemical Response) to Interferon Therapy in Japanese Patients with Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2003, 23, 135-141.	0.5	4
155	Dynamics of Hepatitis C Virus Monitored by Real-Time Quantitative Polymerase Chain Reaction During First 2 Weeks of IFN- α 2 Treatment Are Predictive of Long-Term Therapeutic Response. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 389-395.	0.5	7
156	Accurate Prediction of Response to Interferon Therapy by Repeated Measurement of Hepatitis C Virus Core Protein in Patients with Chronic Hepatitis C. <i>Intervirology</i> , 2002, 45, 105-110.	1.2	5
157	Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-alpha treatment. <i>American Journal of Gastroenterology</i> , 2002, 97, 420-426.	0.2	9
158	SEN viruses and treatment response in chronic hepatitis C virus. <i>Lancet, The</i> , 2002, 359, 1780-1781.	6.3	1
159	GB virus C and TT virus infections in Japanese patients with autoimmune hepatitis. <i>Journal of Medical Virology</i> , 2002, 66, 258-262.	2.5	8
160	Changes in hypervariable region 1 in patients with chronic hepatitis C of genotype 1b with biochemical response to interferon. <i>Hepatology Research</i> , 2002, 23, 237-250.	1.8	7
161	Does ascorbic acid prevent retinopathy during interferon therapy in patients with chronic hepatitis C?. <i>Journal of Gastroenterology</i> , 2001, 36, 486-491.	2.3	10
162	Accessory spleen in the pelvis diagnosed by Tc-99m phytate scintigraphy. <i>Annals of Nuclear Medicine</i> , 2001, 15, 263-265.	1.2	17

#	ARTICLE	IF	CITATIONS
163	TRENDS IN THE CAUSES AND OUTCOME OF LIVER CIRRHOSIS DIAGNOSED BY LAPAROSCOPY IN OSAKA, JAPAN DURING THE PAST THREE DECADES. <i>Digestive Endoscopy</i> , 2001, 13, 13-16.	1.3	1
164	Comparison of real-time quantitative polymerase chain reaction with three other assays for quantitation of hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 904-909.	1.4	21
165	Method to detect substitutions in the interferon-sensitivity- α 2 Determining region of hepatitis C virus 1b for prediction of response to interferon therapy. <i>Hepatology</i> , 2001, 33, 241-247.	3.6	15
166	TT virus infection in patients with chronic liver disease of unknown etiology. <i>Journal of Medical Virology</i> , 2000, 62, 392-398.	2.5	16
167	Prevalence of TT virus in patients with fulminant hepatic failure in Japan. <i>Journal of Gastroenterology</i> , 1999, 34, 589.	2.3	13
168	Characteristics of patients with hepatitis C virus with and without GB virus C/Hepatitis G virus Co-infection and efficacy of interferon alfa. <i>Hepatology</i> , 1998, 27, 1388-1393.	3.6	27
169	Prevalence of GBV-C and hepatitis G virus variants in patients with fulminant hepatic failure in Japan. <i>Journal of Hepatology</i> , 1997, 27, 966-972.	1.8	19
170	Does GBV-C cause fulminant hepatitis in Japan?. <i>Lancet, The</i> , 1996, 347, 908.	6.3	65